Download pdf
New avenues in the treatment of ischemic heart disease - Stem cell therapy
- 1 Lanzhou University
- 2 Zunyi Medical University
- 3 Zunyi Medical University
- 4 Lanzhou University
- 5 Lanzhou University
* Author to whom correspondence should be addressed.
Abstract
Faced with the large number of patients with ischemic heart disease and high mortality rates, traditional drug treatments come with the risks of drug resistance and rebound effects after discontinuation, as well as the shortcomings of surgical treatments such as poor blood circulation and the inability to restore necrotic myocardium. This article starts from the perspective of stem cell regenerative medicine, focusing on the stem cell therapy for ischemic heart disease, and provides a comprehensive review of the types of stem cells and transplantation methods. It also includes further summaries and prospects, believing that more comprehensive and improved treatment methods will emerge in the future to benefit patients.
Keywords
Ischemic Heart Disease, Stem Cells, Cell Transplantation
[1]. Xu, J., et al. Mortality in the United States, 2018. NCHS Data in Brief, 2020(355), 1–8.
[2]. MichlerRE.The current status of stem cell therapy in ischemic heart.disease[J].J Cardiac Surgery, 2018, 33(9):520-531.
[3]. Zhou M, Wang H, Zeng X, et al.Mortality, morbidity, and risk factors in China and its provinces, 1990-2017:a systematic analysis for the Global Burden of Disease Study 2017[J].Lancet, 2019, 394(10204):1145-1158.
[4]. SACCARO LF, AIMO A, EMDIN M, et al.Remote Ischemic Conditioning in Ischemic Stroke and Myocardial Infarction:Similarities and Differences.Front Neurol.2021;12:716316.
[5]. LIU C, HAN D, LIANG P, et al.The Current Dilemma and Breakthrough of Stem Cell Therapy in Ischemic Heart Disease.Front Cell Dev Biol.2021;9:636136.
[6]. Rubart M, Soonpaa MH, Nakajima H, et al.Spontaneous and evoked intracellular calcium transients in donor-derived myocytes following intracardiac myoblast transplantation.J Clin Invest.2004, 114 (6) :775-83.
[7]. Li SH, Lai TY, Sun Z, et al.Tracking cardiac engraftment and distribution of implanted bone marrow cells:Comparing intraaortic, intravenous, and intramyocardial delivery.J Thorac Cardiovasc Surg.2009, 137 (5) :1225-33.
[8]. Eguizabal C, Aran B, Chuva de Sousa Lopes SM, et al.Two decades of embry on icstemcells:ahistorical overview[J].Hum Reprod, 2019, 2019(1):3-4.
[9]. Mancuso P, Raman S, Glynn A, et al.Mesenchymal stem cell therapy for osteoarthritis:the critical role of the cell secretome[J].Front Bioeng Biotechnol, 2019, 7:9.
[10]. Menasché P, Vanneaux V, Hagège A, et al.Transplantation of human embryonic stem cell-derived cardiovascular progenitors for severe ischemic left ventricular dysfunction[J].J Am College Cardiol, 2018, 71(4):429-438.
[11]. Beltrami AP, Urbanek K, Kaistura JL, et al.Evidence thathuman cardiac myocytes divide after myocardial infarction[J].N Engl J Med, 2001, 344 (23) :1750-1757.
[12]. Bolli R, Chugh AR, D‘Amario D, et al.Cardiac stem cellsin patients with ischaemic cardiomyopathy (SCIPIO) :initial results of a randomised phaseⅠtrial[J].Lancet, 2011, 378 (9806) :1847-1857.
[13]. Asahara T, Murohara T, Sullivan A, et al.Isolation of putative progenitor endothelial cells for angiogenesis.Science.1997, 275 (5302) :964-967.
[14]. Asahara T, Masuda H, Takahashi T, et al.Bone marrow origin ofendothelial progenitor cells responsible for postnatal vasculogenesisin physiological and pathological neovascularization[J].Circ Res, 1999, 85 (3) :221-228.
[15]. Graham RM, Bishopric NH, Webster KA, et al.Gene and celltherapy for heart disease[J].IUBMB Life, 2002, 54 (2) :59-66.
[16]. Jan VR, Sander FR, Martin JS, et al.Bone Marrow Cell Injection for Chronic Myocardial Ischemia:The Past and the Future.J CardiovascTrans Res.2011, 4 (2) :182-191.
[17]. Mirotsou M, Zhang Z, Deb A, et al.Secreted frizzled related protein 2 (Sfrp2) is the key Akt-mesenchymal stem cell-released paracrine factor mediating myocardial survival and repair.ProcNatlAcadSci USA.2007, 104 (5) :1643-1648.
[18]. Le BK, Ringden O.Immunomodulation by mesenchymal stem cells and clinical experience.Journal of Internal Medicine.2007, 262 (5) :509-525.
[19]. Mangi AA, Noiseux N, kong D, et al.Nat Med, 2003:9 (9) :1195-1201.
[20]. Oswald J, Boxberger S, Jorgensen B, et al.Stem Cells, 2004;22 (3) :377-384.
[21]. Urbanek K, Rota M, Cascapera S, et al.Cardiac stem cells possess growth factor-receptor systems that after activation regenerate the in-farcted myocardium, improving ventricular function and long-term sur-vival[J].Cire Res2005, 97:663-673.
[22]. ZENG B, LIU L, WANG S F, et al.ILK regulates MSCs survival and angiogenesis partially through AKT and mTOR signaling pathways[J].ActaHistochem, 2017, 119(4):400-406.DOI:10.1016/j.acthis.2017.04.003
[23]. SUN D, SONG H L, SHEN Z Y.Research progress in mesenchymal stem cells modified by Heme oxygenase 1[J].Chin J Reparative ReconstrSurg, 2019, 33(7):901-906.DOI:10.7507/1002-1892.201812079.
[24]. Sheng CC, Zhou L, and Hao J.Current stem cell delivery methods for myocardial repair[J].Biomed Res Int, 2013, 2013:547902.
[25]. Gao LR, Wang ZG, Zhu ZM, et al.Effect of intracoronarytransplantation of autologous bone marrow-derived mono-nuclear cells on outcomes of patients with refractory chro-nic heart failure secondary to ischemic cardiomyopathy[J].Am J Cardiol, 2006, 98 (5) :597-602.
[26]. Tse HF, Kwong YL, Chan JK, et al.Angiogenesis in ischaemicmyocardium by intramyocardial autologous bone marrowmononuclear cell implantation[J].Lancet, 2003, 361 (9351) :47-49.
[27]. Perin EC, Dohmann HF, Borojevic R, et al.Transendocar-dial, autologous bone marrow cell transplantation for se-vere, chronic ischemic heart failure[J].Circulation, 2003, 107 (18) :2294-2302.
[28]. Kocher AA, SchusterMD, Szabolcs M I, et al.Neovascu larization ofischem ic myocard ium by human bone-marrow-derived angiob lastsprevents card iomyocyte apoptosis, reduces remodeling and improvescard iac function[J].NatM ed, 2001, 7 (4) :430-6.
[29]. Barbash IM, Chouraqui P, Baron J, et al.Systemic deliveryof bone marrow-derived mesenchymal stem cells to the in-farcted myocardium:feasibility, cell migration, and bodydist ribution[J].Circulation, 2003, 108 (7) :863-868.
[30]. O rlic D, Kajstura J, Ch im enti S, et a.l Mob ilized bone marrow cellsrepair the infarcted heart, improving function and survival[J].ProcNatl Acad Sci USA, 2001, 98 (18) :10344-9.
Cite this article
Guo,X.;Zhang,X.;Gou,J.;Li,W.;Chen,X. (2024). New avenues in the treatment of ischemic heart disease - Stem cell therapy. Theoretical and Natural Science,54,42-48.
Data availability
The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.
Disclaimer/Publisher's Note
The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of EWA Publishing and/or the editor(s). EWA Publishing and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
About volume
Volume title: Proceedings of ICBioMed 2024 Workshop: Workshop on Intelligent Medical Data Analysis for Precision Medicine
© 2024 by the author(s). Licensee EWA Publishing, Oxford, UK. This article is an open access article distributed under the terms and
conditions of the Creative Commons Attribution (CC BY) license. Authors who
publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons
Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this
series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published
version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial
publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and
during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See
Open access policy for details).